Eating Disorders Clinical Trial
Official title:
A Randomized, Multicenter, Treatment-as-usual Controlled Clinical Trial to Evaluate the Safety and Efficacy of Digital Cognitive Behavioral Therapy for Eating Disorder
Verified date | March 2024 |
Source | WELT corp |
Contact | Yujin Lee |
Phone | 82-2-6439-0707 |
info[@]weltcorp.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders. The main questions it aims to answer are: - Is WELT-ED as effective as standard treatment in reducing the symptoms of eating disorders? - Is the WELT-ED safe for use in the target population without causing adverse effects? Participants will: - Undergo assessments to determine their baseline health status and severity of eating disorder symptoms. - Use WELT-ED or receive standard treatment as directed for the duration of the study period (8 weeks). - Participate in assessments to monitor changes in their eating disorder symptoms and any potential side effects.
Status | Recruiting |
Enrollment | 134 |
Est. completion date | August 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 65 Years |
Eligibility | Inclusion Criteria: - Adults aged between 19 and 65 years - Diagnosed with an eating disorder according to ICD-10. F50.0 Anorexia nervosa F50.1 Atypical anorexia nervosa F50.2 Bulimia nervosa F50.3 Atypical bulimia nervosa F50.4 Overeating associated with other psychological disturbances F50.5 Vomiting associated with other psychological disturbances F50.8 Other eating disorders F50.9 Eating disorder, unspecified) - Have a binge eating frequency (as per item 14 of the EDE-Q) of 4 or more times over the past 4 weeks (28 days) at the time of screening. - Able to use a mobile application (app) on a smartphone without difficulty. - After receiving and understanding sufficient information about this clinical trial, voluntarily decides to participate and provides written consent. Exclusion Criteria: - Previously received Cognitive Behavioral Therapy for the treatment of an eating disorder. - Have a history of bariatric surgery (e.g., adjustable gastric band, sleeve gastrectomy, biliopancreatic diversion, Roux-en-Y gastric bypass). - Have a BMI less than 17 kg/m^2 or more than 40 kg/m^2 at the time of screening. - Diagnosed with a major psychiatric disorder according to the MINI. - Have a past or current diagnosis of schizophrenia or bipolar disorder. - At risk of suicide (C-SSRS score of 4 or higher) or have attempted suicide in the past 2 weeks. - Have active and progressive physical illnesses (e.g., congestive heart failure, chronic obstructive pulmonary disease, acute pain), neurological disorders (e.g., cerebrovascular disease), neurodegenerative diseases (e.g., dementia, multiple sclerosis), unstable medical conditions, or a life expectancy of less than 6 months. - Pregnant or planning to become pregnant during the trial period. - Participated in another clinical trial within 4 weeks prior to screening. - Have a history of alcohol or substance abuse. - Considered by the investigator to be unsuitable for participation in this clinical trial for any other reason. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
WELT corp |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adherence (Compliance) to WELT-ED (applicable only to WELT-ED Group) | Adherence at the 8-week mark (Visit 5) is evaluated based on the completion rate of self-monitoring food diaries and the number of logins to the app (applicable only to the experimental group). | 8weeks | |
Other | BMI (Body Mass Index) | The change in BMI from baseline (pre-use) to after 8 weeks of using the medical device (Visit 5) is assessed. BMI = weight (kg) / height (m)^2. | 8weeks | |
Other | WELT-ED App Usage Satisfaction (applicable only to WELT-ED Group) | App usage satisfaction is assessed through a questionnaire at the 8-week mark (Visit 5) (applicable only to the experimental group). | 8 weeks | |
Other | App-Based Lifestyle and Eating Data (applicable only to WELT-ED Group) | The participants' lifestyle habits (Activity data is evaluated as change of number of steps) and eating data are evaluated through self-monitoring food diaries collected via the app. | 8weeks | |
Other | Change in Regular Meal Frequency (applicable only to WELT-ED Group) | Changes in the frequency of meals are assessed through self-monitoring food diaries collected via the app | 8 weeks | |
Primary | Binge Eating Frequency | Change of Binge Eating Frequency (item 14 of the Eating Disorder Examination Questionnaire, EDE-Q) | from baseline (pre-use) to the 8-week point. | |
Secondary | Eating Disorder Examination Questionnaire (EDE-Q) | 28 items divided into four subscales: dietary restraint, concern with eating, concern with body shape, and concern with weight. Excluding frequency questions, it assesses symptoms over the past 4 weeks on a 7-point scale from 0 to 6, where higher scores indicate more problematic eating behaviors and attitudes. | 8 weeks | |
Secondary | Clinical Impairment Assessment (CIA) | Purpose: Evaluates the secondary impairment in three main areas (personal, social, and cognitive) related to eating disorders.
Format: A brief self-report tool consisting of 16 items, scored on a 4-point scale from 0 (no impairment) to 3 (high impairment). Interpretation: Total score ranges from 0 to 48, higher scores indicate greater personal, social, and cognitive impairment due to eating disorders. |
8 weeks | |
Secondary | Patient health questionnaire-9 (PHQ-9) | Purpose: Assesses symptoms of depression based on the diagnostic criteria for major depressive disorder in DSM-IV, focusing on the past two weeks.
Format: Comprises 9 questions related to mood, sleep changes, fatigue, appetite change, guilt, worthlessness, concentration difficulty, restlessness, and suicidal thoughts, scored from 0 (not at all) to 3 (nearly every day). Interpretation: Higher scores indicate more severe symptoms of depression. |
8 weeks | |
Secondary | Generalized anxiety disorder 7-item scale (GAD-7) | Purpose: A screening tool developed to identify symptoms of generalized anxiety disorder, evaluating the severity of related anxiety or worry.
Format: Contains 7 items, with responses ranging from 0 (not at all) to 3 (nearly every day). Interpretation: Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms and greater functional impairment. |
8 weeks | |
Secondary | The EuroQol Visual Analogue Scale (EQ-VAS) | Purpose: Measures the participant's overall health status as part of a quality of life questionnaire.
Format: A visual analogue scale from 0 to 100. Interpretation: Higher scores represent better overall health status. |
8 weeks | |
Secondary | Clinical Global Impression of Improvement (CGI-I) | Purpose: Assesses the degree of improvement or worsening in a participant's overall health status at 4 weeks (Visit 3) and 8 weeks (Visit 5).
Format: Rated on a 7-point scale, with lower scores indicating greater improvement. Interpretation: Designed to provide a description of change over time, emphasizing the clinician's perspective on patient progress. |
8 weeks | |
Secondary | Clinical Global Impression of Severity (CGI-S) | Purpose: Evaluates the overall severity of the participant's condition at baseline, 4 weeks (Visit 3), and 8 weeks (Visit 5).
Format: A 7-point scale is used, with higher scores indicating greater disease severity. Interpretation: Aims to quantify the severity of the condition from a clinical standpoint, offering insight into the disorder's impact on the patient's life. |
8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05656859 -
Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
|
||
Completed |
NCT04085861 -
Mental Health in Dancers; an Intervention Study
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT03050632 -
Effects of Cognitive and Emotional Functioning on Treatment Outcomes
|
N/A | |
Completed |
NCT02567890 -
Swedish Body Project for Prevention of Eating Disorders
|
N/A | |
Completed |
NCT02484794 -
Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application
|
N/A | |
Completed |
NCT02252822 -
Improving Treatment Engagement for Adolescents With Bulimia Nervosa
|
N/A | |
Completed |
NCT02021344 -
Mental Health First Aid for College Students
|
N/A | |
Completed |
NCT00601354 -
Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
|
N/A | |
Completed |
NCT00418977 -
Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
|
N/A | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Completed |
NCT00733525 -
Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa
|
N/A | |
Active, not recruiting |
NCT04779216 -
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
|
Phase 3 | |
Completed |
NCT04433663 -
Eating Disorders, Self Regulation and Mentalization
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Completed |
NCT04509531 -
Building Resilience in Cyberbullying Victims
|
N/A | |
Recruiting |
NCT05730348 -
Mealtime Anxiety in Eating Disorders
|
||
Enrolling by invitation |
NCT05814653 -
A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders
|
N/A |